IBRX ImmunityBio, Inc.

NASDAQ
$6.02

ImmunityBio, Inc. (IBRX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -16.6% since its last earnings release on November 9, 2026.

ImmunityBio Missed Consensus Estimates
Monday, November 9, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 7:30 AM ET
Earnings Whisper
-
vs ($0.14)
Rev est $58.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.55

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ImmunityBio, Inc.

ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.